J.P. Morgan maintained a Buy rating on CeriBell, Inc. on August 14, 2025. Analysts also suggested that AI stocks offer greater upside potential.
1 report, 1 independent
Updated Aug 14
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
J.P. Morgan maintained a Buy rating on CeriBell, Inc. on August 14, 2025. Analysts also suggested that AI stocks offer greater upside potential.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
J.P. Morgan & Co.
U.S. investment bank
Nothing else this week.
Coverage
Newest first; wire copies grouped- Insider MonkeyJ.P. Morgan Maintains a Buy Rating on CeriBell (CBLL) With a $21 PT CeriBell, Inc. (NASDAQ:CBLL) is one of the best medical device stocks to buy according to analysts. J.P. Morgan analyst Robbie Marc